🇺🇸 FDA

Company profile · Sponsor

Biogen

Biogen Idec Ltd

E2E8A40 · EMA pharma GB
Pipeline
20
Drugs
0
Patents
0

Quick answer

Biogen (E2E8A40) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 20 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E2E8A40
Exchange EMA
Company type pharma
Headquarters GB

Pipeline (20)

Search pipeline →

  1. 0.9% Saline, PARACETAMOL , Felzartamab, CETIRIZINE , LORATADINE , FAMOTIDINE , DIPHENHYDRAMINE , LEVOCETIRIZINE , DESLORATADINE , FEXOFENADINE , METHYLPREDNISOLONE

    Biogen

    IgA nephropathy

    phase 3 small molecule active

    1 trial

  2. BIIB059

    Biogen

    1. Lupus Erythematosus, Cutaneous, Subacute 2. Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  3. BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient., BIIB059

    Biogen

    Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  4. BIIB059, BIIB059 placebo is a sterile liquid for injection. The formulation composition of the placebo is identical to that of BIIB059 drug product minus the active ingredient

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  5. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient

    Biogen

    systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  6. BIIB059, Biib059 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of biib059 drug product minus the active ingredient.

    Biogen

    Systemic lupus erythematosus

    phase 3 small molecule active

    1 trial

  7. BIIB067, PL1, Solution for injection, Intrathecal use. [Placebo]

    Biogen

    Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation

    phase 3 small molecule active

    1 trial

  8. BIIB111

    Biogen

    Choroideremia (CHM) X-Linked Retinitis Pigmentosa (XLRP)

    phase 3 small molecule active

    1 trial

  9. Hard capsules, BIIB141

    Biogen

    Friedreich’s ataxia

    phase 3 small molecule active

    1 trial

  10. Plegridy 125 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5ml solution for injection in pre-filled pen., Plegridy 63 micrograms+94 micrograms solution for injection in pre-filled pen, AVONEX 30 micrograms/0.5 ml solution for injection.

    Biogen

    Relapsing Remitting Multiple Sclerosis (RRMS)

    phase 3 small molecule active

    1 trial

  11. SPINRAZA 28 mg, SPINRAZA 50 mg

    Biogen

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  12. SPINRAZA 50 mg, SPINRAZA 28 mg

    Biogen

    Spinal Muscular Atrophy

    phase 3 small molecule active

    1 trial

  13. Saline Solution Basi 9 mg/ml solution for infusion, Felzartamab

    Biogen

    Kidney Transplant Recipients with Late Antibody-Mediated Rejection

    phase 3 small molecule active

    1 trial

  14. TECFIDERA

    Biogen

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  15. Felzartamab, Saline Solution Basi 9 mg/ml solution for infusion

    Biogen

    Treatment of Late Isolated Microvascular Inflammation in Recipients of Kidney Transplants

    phase 2 small molecule active

    1 trial

  16. Matching Placebo tablets without active substance, BIIB122

    Biogen

    Parkinson's Disease

    phase 2 small molecule active

    1 trial

  17. X-vivo 15 (serum-free growth medium manufactured under gmp and commercially available from Lonza)

    Biogen

    Peripherial arterial disease (PAD) & Chronic-Limb Threatening Ischemia (CLTI) patients who have not responded to standard pharmacological treatment or control of risk factors, and/or had a revascularisation with continued presence of smaller vessel (microvasculature) disease, and do not have the option of a revascularization treatment.

    phase 2 small molecule active

    1 trial

  18. BiiB115 placebo is a sterile liquid for injection. the formulation composition of the placebo is identical to that of BIIB115 drug product minus the active ingredient, BIIB115

    Biogen

    Spinal muscular atrophy

    phase 1 small molecule active

    1 trial

  19. Spinraza 12 mg solution for injection

    Biogen

    Spinal Muscular Atrophy

    phase 1 small molecule active

    1 trial

  20. Spinraza 12 mg solution for injection

    Biogen

    Spinal Muscular Atrophy

    approved small molecule active

    1 trial

Frequently asked questions

What is Biogen?

Biogen (E2E8A40) is a pharma company. headquartered in GB. listed on EMA. NovaPharmaNews links 20 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Biogen sponsor?

We track 20 ClinicalTrials.gov-linked programs for Biogen, including 0.9% Saline, PARACETAMOL , Felzartamab, CETIRIZINE , LORATADINE , FAMOTIDINE , DIPHENHYDRAMINE , LEVOCETIRIZINE , DESLORATADINE , FEXOFENADINE , METHYLPREDNISOLONE and 19 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Biogen company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.